Lung cancer crash course

Author/s: 
Wilkinson, A. N.
Date Added: 
April 22, 2023
Journal/Publication: 
Canadian Family Physician
Publisher: 
College of Family Physicians of Canada
Publication Date: 
April 1, 2023
Issue: 
4
Volume: 
69
Pages: 
266-268
Type: 
Meta-analyses, Reviews, and Guidelines
Format: 
Article
DOI (1): 
10.46747/cfp.6904266
PMID (1): 
37072209

RPR Commentary

A concise review of the diagnosis, classification, and treatment and treatment of lung cancer. James W. Mold, MD, MPH

Abstract

Lung cancer has the highest mortality rate of any cancer in Canada, causing 25.5% of all cancer deaths, with a 5-year survival rate of only 19%. More than half of lung cancers are metastatic at diagnosis, with common sites of metastases in the brain, bone, liver, and adrenal glands. Lung cancer is a heterogeneous group of cancers broadly separated into small cell lung cancer (SCLC)—approximately 15% of all lung cancer cases—and non–small cell lung cancer (NSCLC), which is further divided into predominantly adenocarcinoma and squamous cell carcinoma subtypes. More than 80% of lung cancer cases are related to smoking, meaning smoking cessation remains the cornerstone of lung cancer prevention. Low-dose computed tomography is a valuable screening tool for lung cancer that can identify lung cancers at an earlier stage and reduce lung cancer–specific mortality and all-cause mortality. Although lung cancer screening is recommended by the Canadian Task Force on Preventive Health Care, it is currently available in only a few Canadian provinces.

Text Availability

Free full text